Maybe because of "careful" patient selection, but still great: PSA Undetectable in First Patient Cu-67 SAR-bisPSMA

[Maxone73]

Positive results for mCRPC, very positive. Sorry if I have already posted this (my mind is not so sharp lately...was it ever??).

"The first patient with prostate cancer dosed with 2 cycles of 8GBq of 67Cu-SAR-bisPSMA has reached undetectable prostate specific antigen (PSA) levels using PET"

targetedonc.com/view/psa-un...

[KocoPr]

very inspiring. The future looks bright with new radio pharmaceuticals

[Maxone73 in reply to KocoPr]

I hope so, really!

I am trying to contact the main researcher of this trial, we will see...

[Izzygirl1]

I wish my husband could try this!

[Maxone73 in reply to Izzygirl1]

Maybe he could when he feels better: clinicaltrials.gov/study/NC...

[KocoPr]

The patient inclusion and exclusion criteria are not unusual.

[Maxone73 in reply to KocoPr]

I agree but first one and undetectable is great luck (or hopefully the best treatment ever!!)

[tango65]

I was after one treatment with Lu 177 PSMA I&T in 2016 completely free of mets. Now, Lu 177 PSMA 617 (Pluvicto) does not work for me at all.

[Maxone73 in reply to tango65]

Maybe the beast is not expressing PSA anymore?

[tango65 in reply to Maxone73]

It is expressing PSMA if it were not we had not used Lu 177 PSMA.

[KocoPr in reply to tango65]

Very interesting ! Sorry to hear the Lu 177 does not work for you anymore. So your cancer has found a way to survive a radioactive ligand that it still expresses? I know a lot of warriors Lu177 stops working but wonder how the cancer works around it?

[tango65 in reply to KocoPr]

I don't know either, probably fast repopulation of the psma negative cells in the mets.

The cancer has PTEN loss and P53 mutations which are mutations controlling cell division. These mutations allow the cancer cells to divide despite of having many genomic alterations.

[Izzygirl1 in reply to tango65]

I don’t think it’s working for my husband either and we were told all his cancer cells were PSMA

[KocoPr in reply to Izzygirl1]

Your husband’s first pluvicto treatment was 12/26. I think you need more treatments before you can say that it’s not working. It seems when cancer cells are being killed they can give a higher psa number. Did you ever get genetic testing done? On tumor and germline? It wasn’t in your bio.

Also I would ask the plavicto warriors what to expect and for advice on if there is things you can or can’t do to help with treatments.

All the best for your husband.

where is he being seen? At consult with MSK I would ask them to be your OC team.

[Izzygirl1 in reply to KocoPr]

Had genetic testing… didn’t show anything.

Our next Pluvicto is 2/6. PSA is very low.

Speaking to radiologist at 10am.

I will reach out to the pluvicto warriors!

Husband is being treated at cancer center affiliated with MSK in Hartford CT. MSK agrees with treatment plan so far and has said we were on the right course.

Thank you for replying ! 🩷

[Shams_Vjean]

Exciting news! I’m guessing this is another Alpha particle emitter therapy, based on the principle Investigator for the Trial. Anyone know if that’s the case or not?

[KocoPr in reply to Shams_Vjean]

I think it is a beta particle emitter but I can’t tell from this article.

ncbi.nlm.nih.gov/pmc/articl...

Introduction

Copper-67 (67Cu) (t1/2 = 2.58 d), the longest-living radioisotope of Cu, is of paramount importance because of its simultaneous emissions of β− radiation (mean β− energy: 141 keV; Eβ−max: 562 keV), useful for therapeutic treatments and γ-rays (93 and 185 keV), suitable for single-photon emission computed tomography (SPECT) imaging. In fact, the 67Cu mean β−-emission energy of 141 keV (Eβ−max: 562 keV) is slightly higher than that of Lutetium-177 (177Lu, β−-emission energy of 133.6 keV, Eβ−max: 497 keV). 67Cu decay characteristics make it one of the most promising theranostic radionuclides and its long half-life makes it suitable for imaging in vivo slow pharmacokinetics, such as monoclonal antibodies (MoAbs) or large molecules [1]. 67Cu, studied for decades for radioimmunotherapy [2,3,4], is currently under the spotlight in the international community, as highlighted by the recent IAEA Coordinated Research Project (CRP) on “Therapeutic Radiopharmaceuticals Labelled with New Emerging Radionuclides (67Cu, 186Re, 47Sc)” (IAEA CRP no. F22053) [5,6]. 67Cu can also be paired with the β+ emitters 64Cu, 61Cu, and 60Cu to perform pretherapy biodistribution determinations and dosimetry using positron emission tomography (PET) systems. Table 1 presents the decay characteristics of 67Cu and 64/61/60Cu-radionuclides, as extracted from the NuDat 3.0 database [7].

[Shams_Vjean in reply to KocoPr]

Yup! Beta.

[KocoPr in reply to Shams_Vjean]

epa.gov/radiation/radiation....

“Beta particles are more penetrating than alpha particles, but are less damaging to living tissue and DNA because the ionizations they produce are more widely spaced. They travel farther in air than alpha particles, but can be stopped by a layer of clothing or by a thin layer of a substance such as aluminum. Some beta particles are capable of penetrating the skin and causing damage such as skin burns. “

[j-o-h-n]

You didn't post this before...... cause I remember you didn't.

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 01/18/2024 5:35 PM EST